CVS Health Corporation
NYSE:CVSMedical - Healthcare Plans
-$0.59 today
- Market cap
- $104.08B
- Beta
- 0.62
- P/E (TTM)
- 42.8
- EPS (TTM)
- $2.30
- Dividend yield
- 2.70%
Volume 17.19M
Average 8.19M
CVS Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
CVS Health CorporationNYSE: CVS
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit growth accelerates
Q2 FY2026 gross profit of $15.75B rose 15.9% year over year, ahead of the +9.9% change in trailing-twelve-month gross profit. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +0.5% a year.
Context
- Gross profit amounted to 13.8% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +15.9% holds above the trailing-twelve-month pace of +9.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 55.36B USD
- Year-over-year change
- +7.7%
- 4-year CAGR
- +1.5%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.36B | +7.7% |
| FY2024 | 2024-12-31 | 51.4B | -5.6% |
| FY2023 | 2023-12-31 | 54.43B | -0.1% |
| FY2022 | 2022-12-31 | 54.5B | +4.6% |
| FY2021 | 2021-12-31 | 52.12B | — |
Gross Profit vs competitors
How CVS compares with its peers on the latest reported figures
- CVS's LTM Jun 2026 gross profit of $58.75B is the 3rd highest of the 9 companies compared; the peer median is $24.72B.
- Its year-over-year change of +9.9% is the 6th highest of 9, against a peer median of +31.9%.
- Gross profit amounts to 14.2% of revenue for CVS, versus a peer median of 14.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $102.58B | +19.7% | +1.4% | 22.8% | |
| LTM Sep 2026 | $73.78B | +44.2% | +8.4% | 36.6% | |
| LTM Jun 2026 | $58.75B | +9.9% | +0.5% | 14.2% | |
| LTM Jun 2026 | $31.24B | +96.4% | +12.7% | 16.1% | |
| LTM Sep 2026 | $29.39B | +9.3% | +3.4% | 10.3% | |
| LTM Sep 2026 | $20.06B | +6.2% | +3.0% | 13.0% | |
| LTM Jun 2026 | $6.88B | +78.8% | -25.8% | 44.9% | |
| LTM Sep 2026 | $3.52B | -21.7% | +1.2% | 8.1% | |
| LTM Mar 2026 | $527.01M | +51.7% | +38.4% | 12.4% | |
| Peer median (excluding CVS) | $24.72B | +31.9% | +3.2% | 14.6% | |
Competitors are the stored peer set for CVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 292.11B | 322.47B | 357.78B | 372.81B | 402.07B |
| Cost of Revenue | 239.99B | 267.97B | 303.35B | 321.41B | 346.71B |
| Gross Profit | 52.12B | 54.5B | 54.43B | 51.4B | 55.36B |
| Gross Margin | 17.8% | 16.9% | 15.2% | 13.8% | 13.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 41.23B | 0 |
| Operating Expenses | 38.81B | 46.55B | 40.69B | 42.89B | 44.98B |
| Depreciation & Amortization | 4.49B | 4.22B | 4.37B | 4.6B | 4.61B |
| EBITDA | 17.53B | 12.35B | 18.2B | 13.68B | 9.86B |
| EBITDA Margin | 6.0% | 3.8% | 5.1% | 3.7% | 2.5% |
| Operating Income | 13.31B | 7.95B | 13.74B | 8.52B | 10.39B |
| Operating Margin | 4.6% | 2.5% | 3.8% | 2.3% | 2.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.5B | 2.29B | 2.66B | 2.96B | 3.12B |
| Other Income / Expenses | (2.77B) | (2.12B) | (2.57B) | (2.37B) | (8.25B) |
| Income Before Tax | 10.54B | 5.84B | 11.17B | 6.15B | 2.14B |
| Pre-Tax Margin | 3.6% | 1.8% | 3.1% | 1.6% | 0.5% |
| Income Tax Expense | 2.55B | 1.51B | 2.81B | 1.56B | 408M |
| Net Income | 8B | 4.31B | 8.34B | 4.61B | 1.77B |
| Net Margin | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| EPS (Basic) | 6.00 | 3.29 | 6.49 | 3.66 | 1.40 |
| EPS (Diluted) | 5.95 | 3.26 | 6.47 | 3.66 | 1.39 |
| Weighted Avg Shares | 1.32B | 1.31B | 1.29B | 1.26B | 1.27B |
| Weighted Avg Shares (Diluted) | 1.33B | 1.32B | 1.29B | 1.26B | 1.27B |
CVS Health Corporation
NYSE:CVS
Intrinsic Alpha fair value
Locked
Current Price
$81.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.